Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Blood (2023) 142 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2023-189040

Published: 2023

Journal Articles

An Ongoing Pilot Study of Targeted Radioimmunotherapy (131-I Apamistamab) Conditioning Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Mark B. Geyer, Briana Cadzin, Kinga Hosszu, Brigitte Senechal, Jennifer A. Spross, Alexis Mark, Avinash Desai, Elizabeth R. Cathcart, M. Lia Palomba, Neeta Pandit-Taskar

Blood (2022) 140 (Supplement 1): 10341–10342.

https://doi.org/10.1182/blood-2022-167962

Published: 2022

Journal Articles

Iomab with Adoptive Cellular Therapy (Iomab-ACT): A Pilot Study of 131-I Apamistamab Followed By CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Mark B. Geyer, Briana Cadzin, Elizabeth Halton, Peter Kane, Brigitte Senechal, Eileen M. Geoghegan, Vijay Reddy, Mark S. Berger, Dale Ludwig, Neeta Pandit-Taskar, Craig S. Sauter

Blood (2021) 138 (Supplement 1): 4810.

https://doi.org/10.1182/blood-2021-144994

Published: 2021

Journal Articles

Feasibility of Administering Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC

Bae P Chu, MPH, Neeta Pandit-Taskar, MD, Boglarka Gyurkocza, MD, Qing Liang, PhD, Daniel Miodownik, MPH, Vijay Reddy, MD PhD, Mark S. Berger, MD, Lawrence T. Dauer, PhD

Blood (2019) 134 (Supplement_1): 5839.

https://doi.org/10.1182/blood-2019-131230

Published: 2019

Journal Articles

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Todd L. Rosenblat, MD, Michael R. McDevitt, PhD, Neeta Pandit-Taskar, MD, Jorge A. Carrasquillo, MD, Suzanne M. Chanel, RN, Kevin Zikaras, BS, Mark G. Frattini, MD, PhD, Peter G. Maslak, M.D., Dragan Cicic, MD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD

Blood (2011) 118 (21): 768.

https://doi.org/10.1182/blood.V118.21.768.768

Published: 2011

Journal Articles

Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML)

Todd Rosenblat, MD, MS, Michael R. McDevitt, PhD, Deborah A. Mulford, MD, Neeta Pandit-Taskar, MD, Mark A. Weiss, MD, Mark L. Heaney, MD, PhD, Suzanne Chanel, RN, Alfred Morgenstern, PhD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD, Joseph G. Jurcic, MD

Blood (2008) 112 (11): 2983.

https://doi.org/10.1182/blood.V112.11.2983.2983

Published: 2008

Journal Articles

Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response

Heather Landau, MD, Hani Hassoun, MD, Adam Cohen, MD, Elizabeth Hoover, Tarun Kewalramani, MD, Adam Boruchov, MD, Virginia Klimek, MD, Lillian Reich, MD, Elyn Riedel, Neeta Pandit-Taskar, MD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2008) 112 (11): 3712.

https://doi.org/10.1182/blood.V112.11.3712.3712

Published: 2008

Journal Articles

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML).

Todd L. Rosenblat, MD, Michael R. McDevitt, PhD, Neeta Pandit-Taskar, MD, Jorge A. Carrasquillo, MD, Suzanne Chanel, RN, Mark G. Frattini, MD, PhD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD, Joseph G. Jurcic, MD

Blood (2007) 110 (11): 910.

https://doi.org/10.1182/blood.V110.11.910.910

Published: 2007

Journal Articles

Early Safety and Efficacy Analysis of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) for Elderly High Risk Patients with Untreated DLBCL.

Paul A. Hamlin, MD, Craig H. Moskowitz, MD, Brett C. Wegner, Carol S. Portlock, MD, David J. Straus, MD, Ariela Noy, MD, Otilia Dumitrescu, MD, Maria Lia Palomba, Steven M. Horwitz, MD, Owen A. O’Connor, MD, PhD, Neeta Pandit-Taskar, MD, Chaitanya Divgi, MD, Andrew D. Zelenetz, MD, PhD

Blood (2005) 106 (11): 926.

https://doi.org/10.1182/blood.V106.11.926.926

Published: 2005

Journal Articles

Frequency of Molecular and PET/CT Complete Remissions in Patients with Multiple Myeloma after Autologous Followed by Reduced-Intensity Allogeneic Stem Cell Transplants.

Ping Zhou, MD, PhD, Hugo Castro-Malaspina, MD, Esperanza B. Papadopoulos, MD, James W. Young, MD, Kenneth Miller, MD, Neeta Pandit-Taskar, MD, Daniel A. Filippa, MD, Martin Fleisher, PhD, Raymond L. Comenzo, MD

Blood (2004) 104 (11): 5113.

https://doi.org/10.1182/blood.V104.11.5113.5113

Published: 2004

Journal Articles

Sequential Therapy with Cytarabine and Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML).

Deborah A. Mulford, M.D., Neeta Pandit-Taskar, M.D., Michael R. McDevitt, Ph.D., Ronald D. Finn, Ph.D., Mark A. Weiss, M.D., Christos Apostolidis, Ph.D., Alfred Morgenstern, Ph.D., Chaitanya R. Divgi, M.D., Steven M. Larson, Ph.D., David A. Scheinberg, M.D., Ph.D., Joseph G. Jurcic, M.D.

Blood (2004) 104 (11): 1790.

https://doi.org/10.1182/blood.V104.11.1790.1790

Published: 2004

NARROW

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

An Ongoing Pilot Study of Targeted Radioimmunotherapy (131-I Apamistamab) Conditioning Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Iomab with Adoptive Cellular Therapy (Iomab-ACT): A Pilot Study of 131-I Apamistamab Followed By CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Feasibility of Administering Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML)

Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML).

Early Safety and Efficacy Analysis of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) for Elderly High Risk Patients with Untreated DLBCL.

Frequency of Molecular and PET/CT Complete Remissions in Patients with Multiple Myeloma after Autologous Followed by Reduced-Intensity Allogeneic Stem Cell Transplants.

Sequential Therapy with Cytarabine and Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only